• 1
    Liu PI, Ishimaru T, McGregor DH, Yamamoto T, Steer A. Autopsy study of granulocytic sarcoma (chloroma) in patients with myelogenous leukemia, Hiroshima-Nagasaki 1949–1969. Cancer 1973; 31: 94855.
  • 2
    Muss HB, Moloney WC. Chloroma and other myeloblastic tumors. Blood 1973; 42: 7218.
  • 3
    Byrd JC, Edenfield WJ, Shields DJ, Dawson NA. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol 1995; 13: 180016.
  • 4
    Pileri SA, Ascani S, Cox MC et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 2007; 21: 34050.
  • 5
    Struhal W, Oberndorfer S, Lahrmann H et al. Myeloid sarcoma in the central nervous system: case report and review of the literature. Acta Clin Croat 2008; 47: 1924.
  • 6
    Widhalm G, Dietrich W, Müllauer L et al. Myeloid sarcoma with multiple lesions of the central nervous system in a patient without leukemia. Case report. J Neurosurg 2006; 105: 9169.
  • 7
    Kumar J, Seith A, Bakhshi S, Kumar R, Kumar A, Sen S. Isolated granulocytic sarcoma of the orbit. Eur J Haematol 2007; 78: 456.
  • 8
    Bhattacharjee K, Bhattacharjee H, Das D et al. Chloroma of the orbit in a non-leukemic adult: a case report. Orbit 2003; 22: 2937.
  • 9
    Kamble R, Kochupillai V, Sharma A et al. Granulocytic sarcoma of uterine cervix as presentation of acute myeloid leukemia: a case report and review of literature. J Obstet Gynaecol Res 1997; 23: 2616.
  • 10
    Eggener SE, Abrahams A, Keeler TC. Granulocytic sarcoma of the testis. Urology 2004; 63: 5845.
  • 11
    van der Weide M, Imandt LM, Langenhuijsen MM. Motility of leukaemic cells in acute leukaemia related to tumour mass, maturation and FAB classification. Acta Haematol 1988; 80: 349.
  • 12
    Yamazaki M, Komiyama A, Yamazaki T et al. Leukaemia cell mobility in childhood acute myeloid leukaemia based on the FAB classification. Scand J Haematol 1985; 35: 4816.
  • 13
    Iizuka Y, Aiso M, Oshimi K et al. Myeloblastoma formation in acute myeloid leukemia. Leuk Res 1992; 16: 66571.
  • 14
    Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH. Investigation of karyotypic, morphologic, and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 1994; 8: 8236.
  • 15
    Cross AH, Goorha RM, Nuss R et al. Acute myeloid leukemia with t-lymphoid features: a distinct biologic and clinical entity. Blood 1988; 72: 57987.
  • 16
    Schwonzen M, Kuehn N, Vetten B, Diehl V, Pfreundschuh M. Phenotyping of acute myelomonocytic (AMMOL) and monocytic leukemia (AMOL): association of T-cell-related antigens and skin-infiltration in AMOL. Leuk Res 1989; 13: 8938.
  • 17
    Tallman MS, Hakimian D, Shaw JM, Lissner GS, Russell EJ, Variakojis D. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol 1993; 11: 6907.
  • 18
    Swirsky DM, Li YS, Mathews JG, Flemans RJ, Rees JK, Hayhoe FG. 8;21 chromosomal translocation in acute granulocytic leukemia: cytogenetical, cytochemical, and clinical features. Br J Haematol 1984; 56: 199213.
  • 19
    Xavier SG, Fagundes EM, Hassan R et al. Granulocytic sarcoma of the small intestine with CBFbeta/MYH11 fusion gene: report of an aleukaemic case and review of the literature. Leuk Res 2003; 27: 10636.
  • 20
    Fujieda A, Nishii K, Tamaru T et al. Granulocytic sarcoma of mesentery in acute myeloid leukemia with CBFB/MYH11 fusion gene but not inv(16) chromosome: case report and review of literature. Leuk Res 2006; 30: 10537.
  • 21
    Byrd JC, Weiss RB, Arthur DC et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol 1997; 15: 46675.
  • 22
    Felice MS, Zubizarreta PA, Alfaro EM et al. Good outcome of children with acute myeloid leukemia and t(8;21)(q22;q22), even when associated with granulocytic sarcoma: a report from a single institution in Argentina. Cancer 2000; 88: 193944.
  • 23
    Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-Operative Group. Br J Haematol 1976; 33: 4518.
  • 24
    Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2008.
  • 25
    Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 232233.
  • 26
    Miyawaki S, Tanimoto M, Kobayashi T et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 Study. Japan Adult Leukemia Study Group. Int J Hematol 1999; 70: 97104.
  • 27
    Ohtake S, Miyawaki S, Kiyoi H et al. Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 Study. Int J Hematol 2010; 91: 27683.
  • 28
    Sakamaki H, Miyawaki S, Ohtake S et al. Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 Study. Int J Hematol 2010; 91: 28492.
  • 29
    Ohtake S, Miyawaki S, Fujita H et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: JALSG AML201 Study. Blood 2011; 117: 235865.
  • 30
    Chevallier P, Mohty M, Lioure B et al. Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. J Clin Oncol 2008; 26: 49403.